Sign in
WithdrawnNo phase

Optimal Tailored Treatment for H. Pylori Infection

Key facts

Who runs it
Incheon St.Mary's Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
1 Sept 2020
Ended
1 Oct 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)
Record updated
16 May 2024
Why it stopped
The study design was changed.

Who can take part

Age
19 years to 79 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • consecutive subjects who underwent upper gastrointestinal endoscopy and who had a confirmed diagnosis of H pylori infection

Who cannot take part

  • subjects who had previous gastric surgery
  • subjects with serious concurrent illness
  • subjects with a history of H pylori eradication
  • subjects with a history of allergy to any one of the compounds in this study
  • subjects younger than 18 years old
  • subjects who were pregnant or lactating
  • subjects who were administered antibiotics, bismuth, or PPIs in the 8 weeks preceding the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The efficacy of the current standard triple therapy is at an unacceptably low level. Resistance to antibiotics is suspected to be the major cause of the low efficacy of standard triple therapy. Point mutations in the 23S rRNA gene are known to be the primary mechanism of clarithromycin resistance against H pylori. Recently, a point mutation detection kit using a dual-priming oligonucleotide (DPO)-based multiplex polymerase chain reaction (PCR) assay was introduced and made commercially available. The primary goal of our study was to compare the eradication rates of empirical therapy and tailored therapy. Specifically we examined the eradication rates of 7-d, 14-d empirical therapy with 7-d, 14-d tailored therapy. Our secondary goal was to examine the adverse events of each treatment, cost effectiveness of each treatment methods, and accuracy of DPO-PCR for detecting H. pylori resistance.

The 2 groups in the trial

  • Empirical therapy for H. pylori infectionExisting treatment, for comparison

    The empirical group receives triple therapy of 7 or 14 days for H. pylori eradication

    Treatment: Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)

  • Tailored therapy for H. pylori infectionTreatment being tested

    The tailored therapy group receives eradication regimens based on their DPO-PCR results. Triple therapy of 7 or 14 days for clarithromycin sensitive patients based on DPO-PCR and bismuth quadruple therapy of 7 or 14 days for clarithromycin resistant patients based on DPO-PCR.

    Treatment: Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimal Tailored Treatment for H. Pylori Infection According to the Presence of DPO-PCR Based Clarithromycin Resistance
Record updated
16 May 2024